Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avapritinib - Blueprint Medicines

Next Previous
Drug Profile

Avapritinib - Blueprint Medicines

Alternative Names: AYVAKIT; BLU 285; CS 3007

Latest Information Update: 16 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Blueprint Medicines
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules; Triazines
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic mastocytosis; Gastrointestinal stromal tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Gastrointestinal stromal tumours
  • Phase II Haematological malignancies; Systemic mastocytosis
  • Phase I Solid tumours

Most Recent Events

  • 09 Jan 2020 Registered for Gastrointestinal stromal tumours (Inoperable/Unresectable, Metastatic disease) in USA (PO)-first global approval
  • 09 Jan 2020 FDA assigns PDUFA action date of 14/02/2020 for avapritinib for fourth-line Gastrointestinal stromal tumours
  • 09 Jan 2020 Additional efficacy data from the phase I NAVIGATOR trial in Gastrointestinal stromal tumour released by Blueprint Medicines
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top